Substance / Medication

Avanafil

Overview

Active Ingredient
avanafil
RxNorm CUI
1291301

Indications

Avanafil tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction in adult males.

Labeler: Camber Pharmaceuticals, Inc.Updated: 2025-12-17T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

4
Total Trials
0
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Evaluation of daily avanafil efficacy in improving the endothelial function in Egyptian males with erectile dysfunction.
Elkamshoushi Abdelaal M, Badae Noha M, Kabary Mohamed G et al. · Andrologia · 2021
PMID: 33112433RCT
Avanafil - a further step to tailoring patient needs and expectations.
Boeri Luca, Capogrosso Paolo, Ventimiglia Eugenio et al. · Expert Rev Clin Pharmacol · 2016
PMID: 27232892Observational
The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis.
Corona Giovanni, Rastrelli Giulia, Burri Andrea et al. · Expert Opin Drug Saf · 2016
PMID: 26646748Observational
Avanafil for the treatment of erectile dysfunction.
Zurawin Jonathan L, Stewart Carrie A, Anaissie James E et al. · Expert Rev Clin Pharmacol · 2016
PMID: 27416913Observational
Effect of avanafil on rat and human corpus cavernosum.
Gur S, Sikka S C, Pankey E A et al. · Andrologia · 2015
PMID: 25233953Observational
The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis.
Wang Hongtao, Yuan Jinqiu, Hu Xiaolong et al. · Curr Med Res Opin · 2014
PMID: 24701971Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Avanafil (substance)
SNOMED CT
703956007
UMLS CUI
C2698280
RxNorm CUI
1291301
Labeler
Camber Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.